What We're Reading: Page 103
Industry reads hand-picked by our editors
Sep 12, 2022
Sep 09, 2022
-
BioCentury
FDA: ‘reasonable expectation’ of user fee reauthorization
-
Endpoints News
‘Discriminatory and dangerous’: Pharma companies and advocates slam Texas judge’s HIV coverage decision
-
Bloomberg
The FDA Is Rushing a New and Unproven ALS Drug
-
BioSpace
Arcutis Snaps Up Ducentis Bio to Bolster Atopic Dermatitis Pipeline
Sep 08, 2022
-
Evaluate Pharma
Esmo 2022 – the new liver cancer entrants line up
-
Reuters
Botox rival from Revance gets U.S. approval
-
Financial Times
Oxford’s malaria jab spurs high, sustained protection in children
-
MIT Technology Review
A memory prosthesis could restore memory in people with damaged brains
Sep 07, 2022
Sep 06, 2022
-
The Wall Street Journal
A Spark of Life After Death Points to New Hope for Blindness
-
Bloomberg
China Approves World’s First Covid Vaccine You Inhale
-
Financial Times
US lab at the centre of legal fight over Zantac and cancer
-
Healthcare Dive
CVS nabs home healthcare company Signify for $8B following bidding war
Sep 02, 2022
-
Bloomberg
Drug Recalls for Nitrosamines Could Cost Big Pharma Millions
-
FierceBiotech
Beyond headlines and amyloid, the Alzheimer’s pipeline chugs along
-
BioCentury
Inflation act has slashed value of small molecules: Lilly’s Ricks
-
Endpoints News
Pfizer reshuffles top leadership to hone commercial strategy, leaving room for new rare disease chief
Previous
